Teresa M. Palomero Vazquez, PhD

Profile Headshot

Overview

Academic Appointments

  • Associate Professor of Pathology & Cell Biology at CUMC

Credentials & Experience

Education & Training

  • PhD, University of Oviedo (Spain)

Research

My research program focuses on the elucidation of the genetic and molecular bases of T-cell leukemia and lymphoma, with special interest in the development of targeted therapies for the treatment of these aggressive hematologic tumors.

During my early research career as a postdoctoral associate in the Dana Farber Cancer Institute under the supervision of Dr Thomas Look I participated in pioneer work in the development of the ChIP-on-chip technique in collaboration with Dr. Rick Young at the Broad Institute and applied this method to the characterization of the transcriptional regulatory networks downstream of the TAL1 oncogene in T-cell acute lymphoblastic leukemia (Palomero et al., Blood, 2006). After joining the faculty at Columbia University in 2005 I used gene expression profiling, ChIP-on-chip and ChIP-seq analysis for the identification of NOTCH1 direct target genes responsible for the transformation of T-cell progenitors (Palomero et al., PNAS 2006; Palomero et al., Nat Med 2007; Margolin et al., PNAS 2009; Real et al., Nat Med 2009) and identified mutations in PTEN as responsible for resistance to gamma secretase inhibitor therapy in T-ALL (Palomero et al., Nat Med 2007) and RUNX1 as a novel tumor suppressor in T-ALL (Della Gatta et al, 2012).

Over the last years I have leveraged the power of next generation sequencing approaches to identify novel oncogenes and tumor suppressors in T-ALL (van Vlierberghe and Palomero et al, 2009) and peripheral T-cell lymphomas (Palomero et al., Nat Genet 2014; da Silva Almeida et al., Nat Genet, 2015) and drivers of resistance to chemotherapy in relapsed leukemias (Tzoneva et al., Nat Med 2013; Oshima et al., PNAS 2016).

My current research focuses on the elucidation of the oncogenic mechanisms driven by these genetic alterations, the development of genetically manipulated mouse models of T-cell lymphoma and the therapeutic targeting of key oncogenic pathways responsible for T-cell transformation.

Grants

BRINGING NEW ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA THERAPIES TO THE CLINIC. (Private)

Oct 1 2016 - Sep 30 2019

FUNCTIONAL DISSECTION OF ONCOGENIC ENHANCERS IN T-CELL LEUKEMIA (Private)

Jul 1 2014 - Jun 30 2017

MECHANISMS AND TARGETED INHIBITION OF NT5C2 MUTATIONS IN RELAPSED ALL (Private)

Jul 1 2014 - Jun 30 2016

CLONAL EVOLUTION AND CHEMOTHERAPY RESISTANCE IN ALL (Private)

Jan 1 2014 - Dec 31 2015

THE ROLE OF PHF6 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

Dec 3 2010 - Nov 30 2015

THE GENETICS OF PERIPHERAL T-CELL LYMPHOMAS (Private)

Oct 1 2011 - Sep 30 2014

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 4 1997 - Jun 30 2014

THEROLE OF AKT SIGNALING IN NOTCH1 INDUCED LEUKEMIAS (Federal Gov)

Apr 1 2008 - Jan 31 2014

TARGETING CLASS I PI3KS IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

Aug 1 2010 - Aug 31 2013

NOVEL NOTCH INHIBITORS AND ENHANCERS (Private)

Oct 1 2007 - Sep 30 2012

Selected Publications

Oshima K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, Abate F, Ambesi-Impiombato A, Sanchez-Martin M, Carpenter Z, Penson A, Perez-Garcia A, Eckert C, Nicolas C, Balbin M, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Devidas M, Loh ML, Kirschner-Schwabe R, Palomero T#, Rabadan R#, Ferrando AA# (2016) Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. Sep 21.
(# co-senior authors)

Cortés JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma (2016). Curr Opin Hematol. Jul;23(4):434-43.

da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, Vermeer MH, Rabadan R#, Ferrando A#, Palomero T#. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome (2015) Nat Genet. 47(12):1465-70. PMID: 26551667 (# co-senior authors)

Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA.A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia (2014) Nat Med. 20(10):1130-7. PMID: 25194570

Palomero T*, Couronné L*, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas (2014) Nat Genet. 46(2):166-70. PMID: 24413734
(*Palomero T and Couronné L contributed equally to this work)

Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T#, Rabadan R#, Ferrando A#. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL (2013) Nat Med. 19(3):368-71. PMID: 23377281
(# co-senior authors)

Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersmaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL (2012) Nat Med. 18(3):436-40. PMID: 22366949

De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA. The TLX1 oncogene drives aneuploidy in T cell transformation (2010) Nat Med. 16(11):1321-7. PMID: 20972433

Van Vlierberghe P*, Palomero T*, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. PHF6 mutations in T-cell acute lymphoblastic leukemia (2010) Nat Genet. 42(4):338-42. PMID: 20228800
(*Van Vlierberghe P and Palomero T contributed equally to this work)

Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zúñiga-Pflücker JC, Dominguez M, Ferrando AA. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia (2007) Nat Med. 13(10):1203-10. PMID: 17873882

Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O'Neil J, Neuberg D, Weng AP, Aster JC, Sigaux F, Soulier J, Look AT, Young RA, Califano A, Ferrando AA. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth (2006) Proc Natl Acad Sci U S A. 103(48):18261-6. PMID: 17114293

Palomero T, Odom DT, O'Neil J, Ferrando AA, Margolin A, Neuberg DS, Winter SS, Larson RS, Li W, Liu XS, Young RA, Look AT. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia (2006) Blood 108(3):986-92. PMID: 16621969